Onxeo announces a Combined General Meeting on August 17, 2022
Paris (France), July 12, 2022 – 07:00 pm CEST - Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), hereafter “Onxeo” or the “Company”, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announces that it will hold a Combined General Meeting on Wednesday, August 17, 2022 at 2:00 pm CEST at the Renaissance Paris Nobel Tour Eiffel Hotel, 55 avenue Raymond Poincaré, 75116 Paris.
The meeting notice will be published in the BALO (Bulletin of Mandatory Legal Notices) on July 13, 2022 and will be available through this link.
Shareholders are notably invited to vote on the delisting of the Company from Nasdaq First North market in Copenhagen. This project would allow Onxeo to centralize its listing on Euronext Growth in Paris, the leading platform for biotech stocks in Europe, which would result in increased liquidity.
All documents relating to this general meeting will be uploaded on the Company's website in the General Meetings section within the legal deadlines (15 days prior to the meeting), and shareholders will be notified by a company announcement.
For any question, please contact the Investor Relations team by e-mail at the dedicated address: firstname.lastname@example.org.